化合物PD-1/PD-L1-IN-10 T9616

Product Introduction
Bioactivity


英文名: PD-1/PD-L1-IN-10

描述: PD-1/PD-L1-IN-10 是一种口服有效的PD-1/PD-L1抑制剂 (IC50of 2.7 nM)，显示出抗肿瘤活性。

体外活性: PD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro even at the low concentration of 1 nM[1].PD-1/PD-L1-IN-10 (compound B2) does not affect cell viability of LLC cells and lymph node T-cells[1].PD-1/PD-L1-IN-10 (compound B2, 0-100 nM) stabilizes the PD-L1 protein in mouse Lewis lung carcinoma (LLC) cells. Especially, PD-1/PD-L1-IN-10 (compound B2) maintains the PD-L1 stability in a dose-dependent manner at 58 °C. Suggesting that PD-1/PD-L1-IN-10 (compound B2) could enter LLC cells and then directly binds to the PD-L1 protein[1].

体内活性: PD-1/PD-L1-IN-10在LLC携带的同种异体移植小鼠模型中展现出强大的体内抗癌效果。PD-1/PD-L1-IN-10有效阻止肿瘤细胞的增殖，并在LLC肿瘤组织中诱导凋亡。[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 100 mg/mL (171.93 mM)


关键字: Lewis | T-lymphocyte | tumor | IFN-γ | Inhibitor | PD-1/PD-L1-IN-10 | lung | LLC | inhibit | Apoptosis | PD1/PDL1IN10 | PD 1/PD L1 IN 10 | carcinoma | PD-1/PD-L-1-IN-10

相关产品: CAY10678 | PDL-1 cpd 10 | PD-1/PD-L1-IN-34 | BMS-1166 | Human PD-L1 inhibitor V | PD-L1-IN-3 | Feladilimab | Sasanlimab | LSD1-IN-24 | Peresolimab

相关库: Anti-Liver Cancer Compound Library | Anti-Cancer Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | PPI Inhibitor Library | Orally Active Compound Library | Bioactive Compound Library

化合物PD-1/PD-L1-IN-10 T9616信息由TargetMol中国为您提供，如您想了解更多关于化合物PD-1/PD-L1-IN-10 T9616报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途